Michael Schickler

924 total citations
21 papers, 742 citations indexed

About

Michael Schickler is a scholar working on Molecular Biology, Immunology and Oncology. According to data from OpenAlex, Michael Schickler has authored 21 papers receiving a total of 742 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Molecular Biology, 5 papers in Immunology and 4 papers in Oncology. Recurrent topics in Michael Schickler's work include Reproductive Biology and Fertility (3 papers), Cancer Immunotherapy and Biomarkers (3 papers) and Immunotherapy and Immune Responses (3 papers). Michael Schickler is often cited by papers focused on Reproductive Biology and Fertility (3 papers), Cancer Immunotherapy and Biomarkers (3 papers) and Immunotherapy and Immune Responses (3 papers). Michael Schickler collaborates with scholars based in Israel, United States and Switzerland. Michael Schickler's co-authors include Yoram Groner, Karen B. Avraham, Dan Sapoznikov, Rena Yarom, Haim Y. Knobler, Rinat Rotem‐Yehudar, Baldev Vasir, Kerry Wellenstein, Donald Küfe and David Avigan and has published in prestigious journals such as Cell, Journal of Clinical Oncology and The EMBO Journal.

In The Last Decade

Michael Schickler

19 papers receiving 724 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Michael Schickler Israel	11	323	219	194	110	92	21	742
Maria Lucibello Italy	14	515 1.6×	184 0.8×	152 0.8×	59 0.5×	26 0.3×	21	1.1k
Christine Huppertz Switzerland	16	481 1.5×	154 0.7×	124 0.6×	23 0.2×	110 1.2×	20	910
Maria Flexor France	15	544 1.7×	78 0.4×	61 0.3×	182 1.7×	51 0.6×	24	722
Catherine de Coupade France	14	599 1.9×	246 1.1×	83 0.4×	71 0.6×	12 0.1×	16	857
Marie-Louise Sentman United States	8	160 0.5×	264 1.2×	267 1.4×	37 0.3×	14 0.2×	10	577
Kiyohiko Kishi Japan	21	713 2.2×	134 0.6×	193 1.0×	52 0.5×	18 0.2×	42	1.5k
Sara Caldarola Italy	15	704 2.2×	53 0.2×	191 1.0×	41 0.4×	185 2.0×	19	1.1k
Rebecca J. Burgess United States	14	903 2.8×	96 0.4×	82 0.4×	163 1.5×	39 0.4×	18	1.3k
Wiesława Leśniak Poland	20	800 2.5×	199 0.9×	90 0.5×	18 0.2×	24 0.3×	46	1.0k
Zhiqin Li China	14	265 0.8×	73 0.3×	117 0.6×	43 0.4×	21 0.2×	42	716

Countries citing papers authored by Michael Schickler

Since Specialization

Citations

This map shows the geographic impact of Michael Schickler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Schickler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Schickler more than expected).

Fields of papers citing papers by Michael Schickler

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Schickler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Schickler. The network helps show where Michael Schickler may publish in the future.

Co-authorship network of co-authors of Michael Schickler

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Schickler. A scholar is included among the top collaborators of Michael Schickler based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Schickler. Michael Schickler is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Rosenberg, Ari J., Shumei Kato, Daniel Johnson, et al.. (2024). Abstract 5181: Early activity and biomarker evaluation of NT219 in combination with cetuximab in a Phase 1/2 study of recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). Cancer Research. 84(6_Supplement). 5181–5181.

Rosenberg, Ari, Shumei Kato, Daniel Johnson, et al.. (2024). 27O Interim results of a phase I/II trial of NT219 in combination with cetuximab in patients with advanced/metastatic squamous cell carcinoma of the head and neck (SCCHN). ESMO Open. 9. 102355–102355.

Reuveni, Hadas, et al.. (2023). Abstract B029: CM24, a novel mAb against carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1), suppresses Neutrophil Extracellular Trap (NET)-induced migration and metastasis of cancer cells. Cancer Research. 83(2_Supplement_2). B029–B029. 1 indexed citations

Borazanci, Erkut, Mohammed Najeeb Al Hallak, J. P. Eder, et al.. (2021). 1027TiP A phase Ib study of CM24 in combination with nivolumab in adults with advanced solid tumors, followed by a phase IIa study of CM24 in combination with nivolumab in NSCLC, and in combination with nivolumab and nab-paclitaxel in pancreatic cancer. Annals of Oncology. 32. S861–S861. 2 indexed citations

Bessudo, Alberto, Ezra E.W. Cohen, Daniel Johnson, et al.. (2021). A phase 1/2 study with open-label, dose escalation phase followed by single-arm expansion at the maximum tolerated dose to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of NT219 injection alone and in combination with cetuximab in adults with advanced solid tumors and head and neck cancer.. Journal of Clinical Oncology. 39(15_suppl). TPS3156–TPS3156. 1 indexed citations

Rosenblatt, Jacalyn, Brett Glotzbecker, Heidi Mills, et al.. (2011). PD-1 Blockade by CT-011, Anti-PD-1 Antibody, Enhances Ex Vivo T-cell Responses to Autologous Dendritic Cell/Myeloma Fusion Vaccine. Journal of Immunotherapy. 34(5). 409–418. 237 indexed citations

Rosenblatt, Jacalyn, Brett Glotzbecker, Heidi Mills, et al.. (2010). CT-011, Anti PD-1 Antibody, Enhances Ex-Vivo T Cell Responses To Autologous Dendritic/Myeloma Fusion Vaccine Developed For The Treatment Of Multiple Myeloma. Biology of Blood and Marrow Transplantation. 16(2). S237–S237. 3 indexed citations

Rosenblatt, Jacalyn, Brett Glotzbecker, Heidi Mills, et al.. (2009). CT-011, Anti-PD-1 Antibody, Enhances Ex-Vivo T Cell Responses to Autologous Dendritic/Myeloma Fusion Vaccine Developed for the Treatment of Multiple Myeloma.. Blood. 114(22). 781–781. 5 indexed citations

Pines, Mark, Michael Schickler, S. Hurwitz, & M. Yamauchi. (1996). Developmental Changes in Skin Collagen Biosynthesis Pathway in Posthatch Male and Female Chickens. Poultry Science. 75(4). 484–490. 6 indexed citations

10.

Schickler, Michael, et al.. (1995). Synthesis and phosphorylation of osteopontin by avian epiphyseal growth-plate chondrocytes as affected by differentiation. Comparative Biochemistry and Physiology Part C Pharmacology Toxicology and Endocrinology. 111(1). 49–59. 26 indexed citations

11.

Groner, Yoram, Karen B. Avraham, Michael Schickler, et al.. (1994). Cell damage by excess CuZnSOD and down's syndrome. Biomedicine & Pharmacotherapy. 48(5-6). 231–240. 70 indexed citations

12.

Halevy, Orna, Arieh Gertler, M. Volokita, et al.. (1993). Growth Hormone Receptors in Avian Epiphyseal Growth-Plate Chondrocytes. General and Comparative Endocrinology. 92(2). 179–188. 17 indexed citations

13.

Lira, Sérgio A., Michael Schickler, & Paul M. Wassarman. (1993). cis‐Acting DNA elements involved in oocyte‐specific expression of mouse sperm receptor gene mZP3 are located close to the gene's transcription start site. Molecular Reproduction and Development. 36(4). 494–499. 20 indexed citations

14.

Schickler, Michael, Sérgio A. Lira, Ross A. Kinloch, & Paul M. Wassarman. (1992). A Mouse Oocyte-Specific Protein That Binds to a Region of mZP3 Promoter Responsible for Oocyte-Specific mZP3 Gene Expression. Molecular and Cellular Biology. 12(1). 120–127. 2 indexed citations

15.

Groner, Yoram, Orna Elroy‐Stein, Karen B. Avraham, et al.. (1990). Down syndrome clinical symptoms are manifested in transfected cells and transgenic mice overexpressing the human Cu/Zn-superoxide dismutase gene.. PubMed. 84(1). 53–77. 40 indexed citations

16.

Groner, Yoram, Karen B. Avraham, Michael Schickler, R. Yarom, & Haim Y. Knobler. (1990). Clinical symptoms of Down syndrome are manifested in transgenic mice overexpressing the human Cu/Zn-superoxide dismutase gene.. PubMed. 360. 233–62. 7 indexed citations

17.

Schickler, Michael, Haim Y. Knobler, Karen B. Avraham, Orna Elroy‐Stein, & Yoram Groner. (1989). Diminished serotonin uptake in platelets of transgenic mice with increased Cu/Zn-superoxide dismutase activity.. The EMBO Journal. 8(5). 1385–1392. 49 indexed citations

18.

Avraham, Karen B., Michael Schickler, Dan Sapoznikov, Rena Yarom, & Yoram Groner. (1988). Down's syndrome: Abnormal neuromuscular junction in tongue of transgenic mice with elevated levels of human Cu/Zn-superoxide dismutase. Cell. 54(6). 823–829. 170 indexed citations

19.

Yarom, Rena, et al.. (1988). Premature aging changes in neuromuscular junctions of transgenic mice with an extra human CuZnSOD gene: A model for tongue pathology in Down's syndrome. Journal of the Neurological Sciences. 88(1-3). 41–53. 40 indexed citations

20.

Yron, Ilana, et al.. (1986). The immune system during the pre‐cancer and the early cancer period. IL‐2 production by PBL from post‐menopausal women with and without endometrial carcinoma. International Journal of Cancer. 38(3). 331–338. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact